Ascendia

  MARKET NEWS

Atrogi Announces Positive Clinical Data From First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T Cell Modulators
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
Almirall & Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

  FEATURED EDITORIAL

  COMPANY PROFILE

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2024. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients….

Noramco Announces Strategic Alignment With Purisys & Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API & Drug Product Supply Chain Services Provider

Noramco Announces Strategic Alignment With Purisys & Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API & Drug Product Supply Chain Services Provider

Noramco recently announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired….

Alcami Partners With Tanvex to Offer a Complete Solution for Biologics Developers

Alcami Partners With Tanvex to Offer a Complete Solution for Biologics Developers

Alcami Corporation recently announced a new strategic partnership with Tanvex CDMO, a biologics developer offering pre-clinical to commercial biologic CDMO services. Through the collaboration, Alcami and Tanvex can now offer clients a complete solution from bulk drug substance production through to finished drug product, pairing Alcami’s expertise in liquid and lyophilization sterile filling, packaging, and labeling with Tanvex’s high-throughput bulk drug substance development and manufacturing services.

By adding Alcami’s breadth of sterile fill-finish capabilities and capacity,

 » Read more about: Alcami Partners With Tanvex to Offer a Complete Solution for Biologics Developers  »

Moa to Develop Next-Gen Bioherbicides in New 10-Year Commercial Partnership With Croda

Moa to Develop Next-Gen Bioherbicides in New 10-Year Commercial Partnership With Croda

Deal will accelerate Moa’s development of next-generation bioherbicides, designed to tackle the global threat to food production from increasing weed resistance….

  WHITEPAPERS & WEBINARS

WHITEPAPER -  Long-Acting Injectable Nanoparticle Formulations

WHITEPAPER - Long-Acting Injectable Nanoparticle Formulations

Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution

WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution

While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lines blurring between traditional chemical synthesis …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 27 – Prefilled Syringes
April 3 – Inhalation Delivery